VRCA

Revenue Breakdown: Product revenue was $9.4 million (up from $8.0 million in the prior year period). License and collaboration revenue was $1.5 million (down from $8.2 million, which included a significant milestone payment in the prior year).

Expense Breakdown: Operating expenses totaled $33.7 million. Research and development (R&D) expenses were $9.9 million, driven by the common warts Phase 3 program. Selling, general, and administrative (SG&A) expenses were $20.3 million.

Material Changes vs. Prior Period

• Revenue Decline: Total revenue decreased by $5.3 million compared to the six months ended June 30, 2025. This was primarily due to the absence of an $8.0 million milestone payment from the Torii collaboration recognized in the prior year.
• Increased Loss: Net loss widened to $22.8 million from $9.5 million in the prior year period, driven by higher R&D spend and a legal settlement charge.
• Legal Settlement: The company recorded a $1.7 million net expense (after insurance recovery) related to a settlement of a securities class action lawsuit. A $4.0 million liability was accrued, offset by a $2.3 million insurance recovery asset.
• Debt Reduction: Interest expense decreased significantly ($4.0 million reduction) following the full settlement of the OrbiMed Credit Agreement in November 2025.
• Cash Position: Cash balances decreased from $30.1 million at year-end 2025 to $11.2 million at June 30, 2026, due to operating cash outflows.

Guidance, Outlook, Risks, and Unusual Items

• Going Concern Warning: Management has concluded that substantial doubt exists regarding the company's ability to continue as a going concern within one year of the report date. Current cash ($11.2 million) and the initial tranche of a new credit facility ($12.5 million) are deemed insufficient to fund operations for the next 12 months without additional financing.
• New Financing: On August 3, 2026 (subsequent to the period end), the company entered into a credit agreement with PD Joint Holdings for up to $27.5 million ($12.5 million initially available, $15.0 million contingent on milestones). The loan bears interest at SOFR + 8.0% (minimum 12.5%) and matures in 2030.
• Development Progress: The global Phase 3 program for YCANTH for common warts is ongoing, with top-line data expected in mid-2027. VP-315 for basal cell carcinoma is preparing for Phase 3 trials.
• Risks: Risks include the inability to raise additional capital, failure to meet revenue covenants under the new credit agreement, and the uncertainty of clinical trial outcomes.

Investor Verification Checklist

• Liquidity Runway: Verify the company's ability to access the remaining $15.0 million under the new PD Credit Agreement and the timeline for potential equity raises.
• Legal Settlement Finalization: Confirm the final court approval of the $4.0 million class action settlement and the actual receipt of the $2.3 million insurance recovery.
• Revenue Covenants: Monitor compliance with the minimum annual YCANTH revenue covenant required by the new credit facility.
• Phase 3 Enrollment: Track patient enrollment rates and data timelines for the common warts (COVE-2/COVE-3) and VP-315 clinical trials.
• Customer Concentration: Note that one customer represented approximately 94% of accounts receivable as of June 30, 2026.